Philippe Masset appointed to Vect-Horus board of directors
Ella Day | April 25, 2025 | Appointment | Research and Development | Oncology, Vect-Horus, appointment, board of directors, imaging agents
Vect-Horus has announced the appointment of Philippe Masset to the company’s board of directors. This contributes to a series of senior leadership appointments which are strategic for Vect-Horus’ growth.
Masset is a senior banking executive with a wealth of experience in investment banking, environmental, social and governance (ESG) topics, sustainable finance, and AI. Previously, he led Degroof as CEO between 2014 and 2019, and has held numerous other senior positions at ING. Currently he acts as a senior advisor to financial companies, namely Syntagma Capital and BlackFin.
His financial expertise will support the company’s development of its vectors that deliver therapeutic or imaging agents to organs and tumours.
The appointment follows two prior additions to the board in recent months as part of Vect-Horus’ growth mission. Alexandre Tokay, CEO of Vect-Horus, stated: “This is the third new appointment to the board in recent months, all bringing important skills which are particularly suited to drive our mission to become the leader in the field of targeted drug delivery.”
Tokay commented on Masset’s appointment: “We are delighted that Philippe Masset will be joining our board at this point in time, which adds further highly relevant and senior expertise to Vect-Horus.”
Masset added: “The Vect-Horus board includes hugely experienced individuals who provide important support to management” and that he “is excited to contribute” to its mission.
Ella Day
25/4/25
Related Content
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
